Dermatology最新文献

{"title":"Maternal Diabetes during Pregnancy and Risk of Childhood Psoriasis in Offspring: A National Retrospective Cohort Study.","authors":"Sarah Weissmann, Nir Amitai, Eliya Honig, Amir Horev, Tamar Eshkoli","doi":"10.1159/drm/ackag031","DOIUrl":"https://doi.org/10.1159/drm/ackag031","url":null,"abstract":"<p><p>Objective Maternal diabetes during pregnancy is associated with long-term metabolic and immune-related outcomes in offspring. While psoriasis is strongly linked to metabolic comorbidities later in life, the impact of in utero exposure to maternal diabetes on psoriasis risk in offspring remains unknown. We investigated whether maternal diabetes during pregnancy is associated with the development of childhood psoriasis in offspring. Research Design and Methods We conducted a retrospective population-based cohort study using electronic health record data from Clalit Health Services, Israel's largest health maintenance organization. The cohort included 215,280 singleton live births between 2010 and 2023, with follow-up through 2024. Maternal diabetes during pregnancy was identified using ICD-10 codes and categorized as gestational diabetes, type 1 diabetes, or type 2 diabetes. The primary outcome was childhood psoriasis in offspring. Multivariable Cox proportional hazards analysis adjusted for maternal, pregnancy, and offspring characteristics were used to estimate associations. Results Overall, 5.4% of offspring were born to mothers with diabetes during pregnancy. During follow-up, 1,557 children (0.7%) were diagnosed with psoriasis. Psoriasis prevalence did not differ between offspring exposed and unexposed to maternal diabetes (0.7% vs. 0.7%). No associations were observed by diabetes subtype, treatment modality, or degree of glycemic control. In adjusted analyses, maternal diabetes was not associated with childhood psoriasis in offspring (HR 1.17, 95% CI 0.90-1.54; p = 0.246). Conclusions Maternal diabetes during pregnancy was not associated with increased childhood psoriasis risk in offspring. Our findings do not support a substantial role for prenatal metabolic dysregulation in childhood psoriasis development.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking Status and Psoriasis Risk: An Updated Systematic Review and Meta-Analysis.","authors":"Yixin Ye, Jun Jie Lim, Zongxun Huang, Fook Tim Chew","doi":"10.1159/drm/ackag022","DOIUrl":"https://doi.org/10.1159/drm/ackag022","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 1-5% of the global population. Smoking has long been implicated as a potential environmental risk factor; however, previous studies and meta-analyses have reported heterogeneous and sometimes inconsistent findings. Since the publication of earlier reviews, several large population-based studies have become available, warranting an updated and more comprehensive synthesis of the evidence.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and the Cochrane Library was conducted from database inception to August 8, 2025, following PRISMA guidelines. Cohort, case-control, and cross-sectional studies evaluating the association between smoking status (current or former) and psoriasis risk were included. Adjusted odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using fixed- or random-effects models according to heterogeneity. Subgroup, sensitivity, and publication bias analyses were performed.</p><p><strong>Results: </strong>Sixteen studies were included in the analysis. Both current and former smoking were associated with an increased risk of psoriasis. The pooled OR was 1.89 (95% CI: 1.50-2.39) for current smokers and 1.45 (95% CI: 1.25-1.68) for former smokers, with significant heterogeneity observed across studies. Regional differences were noted: in Asia, the risk for current smokers was notably higher (OR = 2.19, 95% CI: 0.96-4.99), while in Europe and America, the risk for former smokers was higher (Europe: OR = 1.62, 95% CI: 1.46-1.79; America: OR = 1.39, 95% CI: 1.28-1.52). Sensitivity analyses supported the robustness of the findings, and regional variability in the relationship between smoking and psoriasis risk was observed.</p><p><strong>Conclusion: </strong>This updated meta-analysis provides consolidated evidence that smoking is associated with an increased risk of psoriasis, particularly among current smokers. The findings reinforce smoking as a relevant, modifiable risk factor and support its consideration in psoriasis prevention and public health strategies.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopy Features of Port-Wine Birthmarks: A Retrospective Study of 1,136 Cases.","authors":"Peng Wang, Huan Yang, Ruzeng Xue","doi":"10.1159/drm/ackag026","DOIUrl":"https://doi.org/10.1159/drm/ackag026","url":null,"abstract":"<p><strong>Background: </strong>Port-wine birthmarks (PWBs) are congenital capillary malformations affecting approximately 0.3%-0.5% of newborns. - However, large-scale studies characterizing their dermoscopic features remain limited.</p><p><strong>Aims: </strong>This retrospective observational study aimed to analyze the dermoscopic features of 1,136 cases of PWB.</p><p><strong>Methods: </strong>Clinical data and dermoscopic images were retrospectively obtained from 1,136 patients with PWB examined between October 2020 and June 2025. Dermoscopic findings were classified into vascular and nonvascular morphological patterns. Multivariable multinomial logistic regression models were used to assess the associations of dermoscopic morphology with age group, sex, anatomic location, clinical subtype, and previous treatment history.</p><p><strong>Results: </strong>In total, 1,136 patients with PWB were included. Linear vessels were the most common vascular pattern (32.31%). Compared with linear vessels, dotted or globular vessels were more commonly observed on the neck than on the face (aOR 1.95, 95% CI 1.32-2.46, P < 0.01), whereas reticular and mixed vascular patterns were more commonly observed on the trunk and limbs. Hypertrophic PWBs were more likely than pink PWBs to exhibit reticular vessels (aOR 1.86, 95% CI 1.17-2.78, P = 0.01) and mixed vascular patterns (aOR 4.11, 95% CI 2.45-6.01, P < 0.001). Previous treatment was associated with a whitish veil (aOR 7.56, 95% CI 5.44-9.98, P < 0.001) and a pale halo surrounding a central spot (aOR 4.19, 95% CI 2.01-6.32, P < 0.001). Hypertrophic PWBs were also more likely to exhibit both nonvascular features.</p><p><strong>Conclusion: </strong>Our findings demonstrate that dermoscopic vascular and nonvascular patterns are associated with clinical subtype, anatomical location, and previous treatment history in PWB. Prospective studies are warranted to determine whether these dermoscopic features have predictive value for treatment response.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the crosstalk between cancer stemness and the immune microenvironment in melanoma: a single-cell transcriptomic analysis.","authors":"Jiahua Xing, Muzi Chen, Ran Tao","doi":"10.1159/drm/ackag029","DOIUrl":"https://doi.org/10.1159/drm/ackag029","url":null,"abstract":"<p><strong>Background: </strong>Tumor stemness fuels cutaneous melanoma (CM) progression and therapeutic resistance, posing a major challenge in clinical management. However, the spatial architecture of the stem cell niche and the causal genetic drivers orchestrating its maintenance remain elusive.</p><p><strong>Methods: </strong>We employed an integrative multi-omics framework combining single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to map the melanoma stem-like cell (CSC) ecosystem. Computational algorithms, including CytoTRACE (for cellular differentiation inference) and hdWGCNA (for spatial gene network detection), were leveraged to delineate stemness trajectories and their spatially co-localized modules. Furthermore, Mendelian Randomization (MR), a genetic epidemiology method, was applied to evaluate the potential causal roles of candidate genes, thereby moving beyond observational correlations. These findings were validated through immune landscape profiling and pharmacogenomic sensitivity analysis.</p><p><strong>Results: </strong>We identified a stem-like subpopulation confined within a distinct hypoxic niche. MR analysis identified IGFBP7, LGALS1, and RPL10A as potential causal drivers of CM. Mechanistically, we reveal a dual mode of maintenance, IGFBP7 and LGALS1 act extrinsically to construct immune-excluded microenvironments via vascular remodeling and myeloid barriers, whereas RPL10A functions intrinsically to secure biosynthetic capacity via enhanced translation. Pharmacogenomic profiling further supports a mechanism-based therapeutic stratification, revealing subtype-specific vulnerabilities to MAPK inhibitors, taxanes, and platinum agents.</p><p><strong>Conclusion: </strong>By defining the causal spatial architecture of melanoma stemness, this study provides a translational rationale for biomarker-driven patient stratification and mechanism-based therapeutic selection, offering specific strategies to disrupt the CSC niche and overcome therapeutic resistance.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UVA1 Phototherapy in a national reference center:A 10-year systematical analysis.","authors":"Sara Vogel, Reinhard Dummer, Laurence Imhof, Marjam Barysch","doi":"10.1159/drm/ackag024","DOIUrl":"https://doi.org/10.1159/drm/ackag024","url":null,"abstract":"<p><strong>Introduction: </strong>UV A1 phototherapy (340-400 nm) has proven safe and effective for various skin conditions. However, limited published data make it challenging to establish individualized treatment protocols for many of these disorders. This study retrospectively analyzed the efficacy and tolerability of medium-dose UV A1 phototherapy (40-60 J/cm²) for various dermatological conditions.</p><p><strong>Methods: </strong>We performed a single-center retrospective analysis of 249 patients with different dermatoses treated with UVA1 phototherapy between 2010 and 2019 at the Department of Dermatology, University Hospital Zurich. Treatment response was classified as complete, partial, or no response, based on clinical examination, scores, photographic documentation and standardized questionnaires. Patients primarily received medium-dose UV A1 therapy three times weekly. Adverse events were graded according to CTCAE v5.0. All patients were followed up for at least two years.</p><p><strong>Results: </strong>The most common indications were sclerosing dermatoses (39.8%), atopic dermatitis (32.5%), and granuloma annulare (14.9%). The mean single dose was 49.25 J/cm², administered three times weekly, with a mean cumulative dose of 1395.32 J/cm². Overall, 78.3% of patients showed objective clinical improvement, with 14.9% achieving a complete response and 63.5% a partial response. Objective response rates did not differ significantly between diagnostic groups (p = .169). Subjective improvement was reported by 65.9% of patients. Mild adverse events (CTCAE grade I), primarily transient erythema and UV-induced hyperpigmentation, occurred in 26.5% of patients. One patient experienced a moderate adverse event (second-degree burn), and no serious adverse events occurred.</p><p><strong>Conclusion: </strong>Predominantly medium-dose UVA1 phototherapy was associated with a high overall clinical response rate across the main diagnostic groups, with predominantly mild and transient adverse events. These findings support UVA1 phototherapy as an effective treatment option for selected inflammatory and sclerosing dermatoses. Further studies should investigate long-term safety, maintenance protocols, patient-specific factors, and combination therapies.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disgust Sensitivity and Self-Disgust in Individuals with Atopic Dermatitis and Psoriasis.","authors":"Clara Wülfing, Laura Lübke, Alexander Thiem, Steffen Emmert, Carsten Spitzer","doi":"10.1159/drm/ackag027","DOIUrl":"https://doi.org/10.1159/drm/ackag027","url":null,"abstract":"<p><strong>Introduction: </strong>Disgust is an adaptive basic emotion that promotes avoidance of potential pathogen threats through aversive affect and rejection responses. In chronic inflammatory skin diseases, visible skin alterations may function as contamination cues, yet the role of individual differences in disgust sensitivity and self-disgust (comprising personal and behavioral dimensions) remains largely unexplored.</p><p><strong>Methods: </strong>We examined disgust sensitivity and self-disgust in adults with atopic dermatitis and psoriasis, contrasting scores with non-clinical norms and evaluating links to clinical and psychosocial features.</p><p><strong>Results: </strong>In an online survey, 621 participants (N = 339 atopic dermatitis, N = 282 psoriasis) completed measures of disgust sensitivity through the Scale for the Assessment of Disgust Sensitivity (SADS), self-disgust through the Questionnaire for the Assessment of Self-Disgust (QASD), dermatology-related quality of life (DLQI), depressive and anxiety symptoms (PHQ-4), and perceived stress (PSSD). Disgust sensitivity and personal self-disgust scores were frequent and exceeded published non-clinical reference values, whereas behavioral self-disgust was not elevated and was lower among individuals with psoriasis than the corresponding reference values. Group comparisons revealed comparable disgust sensitivity levels in atopic dermatitis and psoriasis, but greater personal self-disgust in atopic dermatitis.</p><p><strong>Discussion: </strong>Disgust sensitivity and self-disgust were systematically associated with lesion visibility, pruritus severity, diminished quality of life, and heightened affective symptoms. These results highlight the clinical importance of measuring disgust sensitivity and particularly self-disgust as an indicator of the psychosocial impact of chronic inflammatory skin diseases.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebriform Nests on Reflectance Confocal Microscopy: Bridging Architecture, Tumor Biology, and Prognosis in Melanoma - A Systematic Review.","authors":"Antonio Alma, Samantha Gherbassi, Alessandro Clementi, Seher Banu Farabi Atak, Nicholas Gulati, Silvana Ciardo, Francesca Beretti, Francesca Farnetani","doi":"10.1159/drm/ackag013","DOIUrl":"10.1159/drm/ackag013","url":null,"abstract":"<p><strong>Introduction: </strong>Noninvasive imaging techniques such as reflectance confocal microscopy (RCM) have recently been used to investigate microscopic features of melanoma to assess its morphology and for prognostic factors. Among the morphologic features identified in melanoma, cerebriform nests represent a distinctive confocal pattern characterized by multilobulated dermal cell aggregates with convoluted, brain-like contours and heterogeneous reflectivity.</p><p><strong>Methods: </strong>The aim of this review was to describe current evidence on the morphological definition, histopathological and molecular correlations, and potential diagnostic and prognostic significance of cerebriform nests in melanoma, as identified by RCM. We included studies conducted on human subjects with diagnosis of melanoma.</p><p><strong>Results and conclusion: </strong>Cerebriform nests' multilobulated architecture reflects a high degree of structural and biological disorganization of the neoplasm, correlated with histopathological parameters of aggressiveness, such as greater dermal depth, vertical growth, high Clark level, and lymphovascular invasion. In the near future, the identification of cerebriform nests using RCM could contribute not only to improving diagnostic accuracy, but also to prognostic stratification and the selection of patients who may be candidates for personalized treatment pathways.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-Year Real-Life Data from Thai Patients with Moderate to Severe Plaque Psoriasis Treated with Secukinumab - Outcomes from the PROMPT Study.","authors":"Pravit Asawanonda, Leena Chularojanamontri, Mati Chuamanochan, Warayuwadee Amornpinyo, Padcha Pongcharoen, Supapat Laodheerasiri, Bensachee Pattamadilok, Charoen Choonhakarn, Siripan Sangmala, Nisa Pretikul, Metavee Boonsiri, Naruemon Sangob, Ploysyne Rattanakaemakorn","doi":"10.1159/drm/ackag023","DOIUrl":"https://doi.org/10.1159/drm/ackag023","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data on secukinumab use in Thai patients with psoriasis is limited. This study evaluates its effectiveness and safety in routine clinical practice.</p><p><strong>Methods: </strong>The PROMPT study is an ongoing, multicenter, 2-year observational study involving patients with moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated with secukinumab. This interim analysis reports one-year outcomes in patients with plaque PsO.</p><p><strong>Results: </strong>A total of 101 patients with moderate to severe plaque PsO were included. The one-year secukinumab retention rate was 80% (95% CI: 75-88%). The most common reasons for discontinuation were financial constraints and lack of reimbursement. Effectiveness outcomes showed a significant reduction in psoriasis area and severity index (PASI) scores, with a mean percentage change of -84% (95% CI: -88 to -79%), and 77 patients achieved PASI 75. Physician's global assessment (PGA) scores also improved significantly, with a median score of 1.0 at 12 months. Health-related quality of life (HRQoL) improved, with a mean utility score increase of 0.2 (95% CI: 0.1-0.2) and a mean DLQI score reduction of -80% (95% CI: -85 to -75%). Only three patients reported adverse drug events, with no serious adverse events observed.</p><p><strong>Conclusion: </strong>Secukinumab demonstrated one-year retention comparable to previous real-world studies, with a favorable safety profilein Thai patients with moderate to severe plaque psoriasis. It significantly improved disease severity and HRQoL in real-world clinical settings.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adalimumab in Generalized Granuloma Annulare: A Systematic Review.","authors":"Guillem Esteve-Boncompte, Ahmed Lulu, Álvaro Lagos Tapia, Paweł Pietkiewicz","doi":"10.1159/drm/ackag006","DOIUrl":"10.1159/drm/ackag006","url":null,"abstract":"<p><strong>Introduction: </strong>Generalized granuloma annulare (GGA) is an uncommon inflammatory dermatosis characterized by smooth annular plaques and papules, frequently demonstrating resistance to conventional therapies. Anti-tumor necrosis factor-α inhibitors, including adalimumab, have been used to treat refractory cases. However, current evidence remains weak, as it is based on small, heterogeneous studies with non-standardized outcome measures. The objective of this article is to systematically review the published literature regarding the efficacy and safety of adalimumab in the treatment of GGA.</p><p><strong>Methods: </strong>A systematic literature search was conducted across PubMed/MEDLINE, Google Scholar, LILACS, Scopus, and Web of Science. Eligible studies included case reports, case series, observational studies, and clinical studies reporting the use of adalimumab in patients diagnosed with GGA. Experimental studies, animal studies, in vitro studies, and editorials were excluded. Data were extracted on patient characteristics, dosing regimens, treatment response, time to response, relapse following discontinuation, and adverse events.</p><p><strong>Results: </strong>Nineteen studies evaluating the use of adalimumab in GGA were included. The majority of patients demonstrated a clinical response, with most achieving complete or partial improvement, while a minority showed no response. Relapses following treatment discontinuation were reported in some cases, underscoring the chronic nature of the disease and the potential need for ongoing therapy. Adalimumab was generally well tolerated, with adverse events reported in a limited subset of patients.</p><p><strong>Conclusion: </strong>The available evidence suggests that adalimumab is a generally safe and well-tolerated therapeutic option for GGA. Larger prospective studies are needed to better determine its efficacy and safety.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the risk of melanoma in people with Parkinson's disease: a systematic review and meta-analysis.","authors":"Upeksha Galappaththie, Amy Weber, Leanne Hall, Clare Heal","doi":"10.1159/drm/ackag025","DOIUrl":"https://doi.org/10.1159/drm/ackag025","url":null,"abstract":"<p><strong>Introduction: </strong>The potential association between Parkinson's disease (PD) and melanoma has received increasing attention in the literature, yet its strength and direction remain incompletely understood. Previous studies vary considerably in diagnostic ascertainment, temporal relationship between the two conditions and analytic approach. This systematic review and meta-analysis aimed to evaluate this association while accounting for these methodological differences.</p><p><strong>Methods: </strong>A comprehensive search of four databases from inception to May 25, 2025 was conducted. Methodological study quality was evaluated using Newcastle-Ottawa Scale and JBI Analytical Cross-sectional checklist. GRADE was applied to assess the overall certainty of evidence. A random-effects model with restricted maximum likelihood estimation and Hartung-Knapp adjustment was performed to calculate pooled odds ratios with 95% confidence intervals. Heterogeneity was assessed using I2.</p><p><strong>Results: </strong>Eighteen studies met the inclusion criteria for this review, of which three were eligible for the meta-analysis. The pooled odds ratio was 2.55 (95% CI: 0.09-73.07). Although the point estimate was above the null, the confidence interval was extremely wide and included an OR of 1.0. Between-study heterogeneity was observed (I2 = 82.2%), and the certainty of evidence was rated as very low.</p><p><strong>Conclusion: </strong>The available evidence regarding the association between PD and melanoma remains very uncertain. Although the pooled OR was above the null, the wide confidence interval, substantial heterogeneity and very low certainty of evidence prevent the drawing of firm conclusions regarding the magnitude or direction of this association. Current evidence is insufficient to support PD-specific melanoma screening recommendations, and further methodologically robust studies are warranted.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1"},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}